Early findings from the ASPIRO trial showed ANPD001 was safe, well-tolerated, and led to marked improvements in motor symptoms and daily functioning.:
Source: Neurology Read More
Parkinson Cell Therapy ANPD001 Generates Promising Early-Stage Phase 1/2 Data
Related Posts
<![CDATA[FDA AdComm Votes Against Recommending
Deramiocel Approval, Tazbentetol Shows Durable Cognitive Benefit in
AD, Salanersen’s FDA Breakthrough Designation
Meaning]]>
<![CDATA[FDA AdComm Votes Against Recommending Deramiocel Approval, Tazbentetol Shows Durable Cognitive Benefit in AD, Salanersen’s FDA Breakthrough Designation Meaning]]>
